Lovenox Patent Invalidity Ruling Could Open Door To Near-Term Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
California court invalidates Sanofi-Aventis’ patent due to inequitable conduct. The court’s ruling will lead to lifting of 30-month stay on ANDA approvals. Amphastar and Teva said they would await FDA approval of their enoxaparin generics before deciding whether to launch prior to an appellate court ruling.
You may also be interested in...
Court Rules Against Sanofi In Lovenox Patent Case Again; Second Round Of Appeals Likely
Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.
Court Rules Against Sanofi In Lovenox Patent Case Again; Second Round Of Appeals Likely
Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.
Lovenox’ Days In Court
Sanofi-Aventis begins a patent challenge case with Sandoz while a similar suit against Amphastar and Teva moves forward.